Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd’s 6th Largest Position

Capricorn Fund Managers Ltd boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 197.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 107,787 shares of the company’s stock after acquiring an additional 71,587 shares during the period. Guardant Health comprises 2.7% of Capricorn Fund Managers Ltd’s portfolio, making the stock its 6th largest holding. Capricorn Fund Managers Ltd owned approximately 0.09% of Guardant Health worth $11,009,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Baillie Gifford & Co. increased its stake in shares of Guardant Health by 6.6% during the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after purchasing an additional 317,906 shares in the last quarter. Invesco Ltd. grew its holdings in Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after buying an additional 763,834 shares during the last quarter. Franklin Resources Inc. grew its holdings in Guardant Health by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after buying an additional 606,368 shares during the last quarter. Nikko Asset Management Americas Inc. increased its position in Guardant Health by 49.6% during the second quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock worth $105,623,000 after buying an additional 673,438 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Guardant Health during the third quarter worth $114,421,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $93.83 on Monday. Guardant Health, Inc. has a twelve month low of $36.36 and a twelve month high of $120.74. The firm has a market capitalization of $12.31 billion, a P/E ratio of -28.35 and a beta of 1.64. The stock’s fifty day simple moving average is $97.07 and its 200 day simple moving average is $92.94.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. The company’s revenue for the quarter was up 39.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.62) earnings per share. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Mizuho set a $135.00 price objective on Guardant Health in a research report on Friday, January 9th. Guggenheim boosted their target price on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Barclays reaffirmed an “overweight” rating and set a $130.00 price target on shares of Guardant Health in a research note on Friday, February 20th. Stifel Nicolaus lifted their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Piper Sandler boosted their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, February 24th. Twenty research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $125.95.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider Terilyn J. Monroe sold 8,571 shares of Guardant Health stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the sale, the director owned 1,193 shares of the company’s stock, valued at approximately $109,207.22. This represents a 52.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 23,250 shares of company stock worth $2,512,917 in the last quarter. Company insiders own 6.10% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.